IP Library Granted Patent US 9,839,628
Granted Patent B2
US 9,839,628 · App. 12/791,586 · Granted Dec 12, 2017

Compositions and methods for preventing sternal wound infections

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,628
App. No.
12/791,586
Granted
Dec 12, 2017
Kind
B2
Abstract

The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be topically applied to an esophageal perforation in a subject or a median sternotomy incision site in the subject, and in which the at least one antimicrobial agent is present in an amount effective to inhibit development of mediastinitis in the subject.

Claims (32)

1. A topical, antimicrobial composition comprising:

poly(DTE-co-DT succinate),

Ostene, and

at least one antimicrobial agent,

wherein the composition is formulated formulated as a malleable and hand-moldable hemostatic putty which functions as a bone wax substitute for covering bony edges and gaps after surgery.

2. The composition according to claim 1 , wherein the antimicrobial agent comprises a combination of minocycline and rifampin.

3. The composition according to claim 1 , wherein the composition is completely bioresorbable.

4. The composition according to claim 1 , wherein the poly(DTE-co-DT succinate) ranges from about 30% to about 80% by total weight of the composition.

5. A topical, antimicrobial composition comprising:

poly(DTE-co-DT succinate);

Ostene; and

an antibiotic,

wherein the antibiotic is selected from the group consisting of tetracyclines, penicillins, macrolides, rifampin and combinations thereof, wherein the composition is formulated as a malleable and hand-moldable hemostatic putty configured which functions as a bone wax substitute for covering bony edges and gaps after surgery.

6. The composition according to claim 5 , wherein the poly(DTE-co-DT succinate) ranges from about 30% to about 80% by total weight of the composition.

7. A topical, antimicrobial composition comprising:

poly(DTE-co-DT succinate);

Ostene;

minocycline; and

rifampin,

wherein the composition is formulated as a malleable and hand-moldable hemostatic putty which functions as a bone wax substitute for covering bony edges and gaps after surgery.

8. The composition according to claim 7 , wherein the poly(DTE-co-DT succinate) ranges from about 30% to about 80% by total weight of the composition.

9. The composition according to claim 1 , wherein the antimicrobial agent comprises minocycline and rifampin, the composition being configured to release about 75% of the minocycline and about 50% of the rifampin within two hours.

10. The composition according to claim 1 , wherein the antimicrobial agent comprises minocycline and rifampin, the composition being configured to release about 51% of the minocycline and about 24% of the rifampin within two hours.

11. The composition according to claim 1 , wherein the antimicrobial agent comprises minocycline and rifampin, the composition being configured to release about 86% of the minocycline and about 73% of the rifampin within twenty four hours.

12. The composition according to claim 1 , wherein the at least one antimicrobial agent is dispersed throughout the poly(DTE-co-DT succinate).

13. The composition according to claim 1 , wherein the antimicrobial agent comprises minocycline and rifampin, the composition more rifampin by weight than minocycline.

14. The composition according to claim 1 , wherein the structure of poly(DTE-co-DT succinate) is represented by the formula

wherein “a” is a number between 0.01 and 0.99 that represents the mole fraction of tyrosine-derived monomer that is esterified and “n” is a number.

15. The composition according to claim 1 , wherein the poly(DTE-co-DT succinate) comprises desaminotyrosyl tyrosine monomers.

16. The composition according to claim 1 , wherein the composition comprises a greater amount of Ostene by weight than the poly(DTE-co-DT succinate).

17. The composition according to claim 1 , wherein the composition comprises 10% w/w of the poly(DTE-co-DT succinate).

18. The composition according to claim 1 , wherein the composition comprises a greater amount of the antimicrobial agent by weight than the poly(DTE-co-DT succinate).

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Feb 10, 2020
From: TYRX, INC.; MEDTRONIC, INC.
To: MEDTRONIC, INC.
Reel/Frame 051770/0976 →
MERGER Recorded May 23, 2014
From: TYRX, INC.
To: TYRX, INC.
Reel/Frame 032954/0407 →
CHANGE OF NAME Recorded Nov 22, 2011
From: TYRX PHARMA, INC.
To: TYRX, INC.
Reel/Frame 027311/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2010
From: BAHULEKAR, RAMAN; MOSES, ARIKHA; PULAPURA, SATISH; MCJAMES, II, WILLIAM C.; BUEVICH, FATIMA
To: TYRX PHARMA, INC.
Reel/Frame 024845/0171 →